Supplement Usage Pattern in a Group of COVID-19 Patients in Tehran

Maryam Bagheri; Ph.D.1, Fedyeh Haghollahi; M.Sc.2, Mamak Shariat; M.D.1, Mina Jafarabadi; M.D.1, Parastoo Aryamloo; M.Sc.4, Elahe Rezayof; B.Sc.2

1 Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
2 Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Maternal, Fetal & Neonatal Research Center, Family Health Institute, Tehran University of Medical Sciences, Tehran, Iran
4 Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Received August 2020; Revised and accepted September 2020

Abstract

Objective: The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection, causes severe acute respiratory syndrome and was spread throughout the world in early 2020. The effects of vitamin and micronutrient supplements on the prevention and treatment of COVID-19 seems challenging in scientific considerations. On the other side generally, experts warn against over-consumption of these supplements.

Materials and methods: This study aimed to investigate the vitamin and micronutrient supplementation usage pattern in past history of patients with COVID-19 via a cross-sectional inquiry. Totally 510 patients referring to the infectious disease clinic of Imam Khomeini Hospital in Tehran from March 2020 to May 2020 were recruited. The inclusion criterion was suspected patients for COVID-19 based on clinical findings and CT scans of the lung. The infected patients included both inpatients (171) and outpatients (339). Demographic information, clinical signs, and the supplement pattern use were collected through a questionnaire and the data were statistically analyzed.

Results: Vitamin D3 intake was reported in 30% (103 patients) of outpatients and 16.5% (28 patients) of hospitalized patients, which is statistically significant (P=0.001). It shows that, the frequency of vitamin D3 consumption in the outpatient group was higher than inpatient group. This significant difference has also been shown in zinc consumption, in 29 patients (9%) outpatients versus 4 patients (2%) inpatients were reported (P=0.007). Multi nominal regression showed that vitamin D3 intake has a supportive effect and reduces the risk of exacerbation and worsening of the disease. (OR=0.291; 95% CI 0.102-0.834, P=0.022).

Conclusion: According to the results of the present study and the findings of other studies, considering the supportive effect of vitamin D3 in reducing the severity of infectious diseases; Clinical trials with an appropriate sample size are recommended to investigate the functional role of this vitamin in improving viral diseases of the respiratory tract.

Keywords: Supplement; COVID-19; Vitamins; Micronutrients
Introduction
The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection that causes severe acute respiratory syndrome and was introduced from Wuhan, Hubei province and was spread throughout the world in early 2020 (1, 2).

The countries around the world experienced numerous problems that threaten public health and have attracted enormous consideration around the world. Also, to date, there are no clinically approved vaccines or antiviral drugs for these human coronavirus infections. However, studies about this new virus are limited (1). Therefore, intensive research on the novel developing human infectious coronaviruses is needed to explain their route of transmission and pathogenic mechanisms and to identify potential drug targets, which would support the development of effective preventive and therapeutic countermeasures (2). Prevention and control of infections and observance of hygienic principles by the general public is a priority. Nutritional and health advice hygiene should be considered more than ever. However, the role of vitamin supplementation in the prevention of many chronic diseases is less well established (3). Evidence is insufficient to prove the presence or absence of benefits from the use of multivitamin and mineral supplements to prevent chronic disease (4). Dietary supplements are widely used and offer the potential to improve health if appropriately targeted to those in need. Inadequate nutrition and micronutrient deficiencies are prevalent conditions that adversely affect global health (5). Some researchers have guessed that people with low serum vitamin D might be at higher risk of infection with COVID-19, or do worse if infected (6). Though, lee et al. "Found no clinical evidence that vitamin D supplements are beneficial in preventing or treating COVID-19 "(7).

A review of randomized clinical trials showed that vitamin D supplementation was associated with reduced respiratory tract infections (8). Numerous clinical data suggest that vitamins, including vitamins A, B6, B12, C, D, E and folate, rare elements, including zinc, iron, selenium, magnesium and copper and omega-3 fatty acids play an important role in supporting the immune system (9, 10).

Also, there is widespread publicity about the effects of vitamin supplements on the prevention and treatment of COVID-19. In other side generally experts warn against over-consumption of these supplements. Therefore, this study aimed to investigate the history of vitamin and micronutrient supplementation pattern use in patients with COVID-19.

Materials and methods
The Ethics Committee of Tehran University of Medical Sciences has approved this study (IR.TUMS.VCR.REC.1398.1063). The present study is a cross-sectional study. Totally 510 patients’ referring to a university hospital infectious clinic from March to May 2020 was recruited in this study. All patients who referred to our hospital with clinical findings of COVID-19 and their diagnosis were confirmed by reviewing CT scans by two expert radiologists, were entered into our study. Two views of ground glass opacity and consolidation in CT scan confirmed by two different radiologists have been considered as diagnosis of COVID-19 (11). The images of CT sometimes appear bilateral pulmonary parenchymal ground-glass and Consolitative pulmonary opacities with a rounded morphology and a peripheral lung distribution when patients are infected with COVID-19 (12). Symptoms (including fever measured in degrees centigrade, dry cough, productive cough, difficulty speaking, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as present, or not. Symptomatic patients who complained of symptoms; in the absence of acute pulmonary symptoms in CT scan, were managed on outpatient setting. Patients were hospitalized if they had shortness of breath (dyspnea) and less than 90 percent of Oxygen saturation (inpatients).

The severity of the disease in patients was divided into three categories: general, severe and critical as follows. General: fever; respiratory symptoms; radiologic findings from pneumonia. Severe: The presence of any of the symptoms of distress (respiratory distress); Respiratory rate more than 30 per minutes, Blood O2 saturation level less than 90% at rest, the ratio of arterial oxygen pressure to the percentage of inspiration oxygen is less than 300 mm and critical: presence of any of the symptoms: respiratory failure, need for mechanical ventilation or artificial respiration, septic shock, extra pulmonary organ failure and transfer to the intensive care unit.

Data collection method was a researcher-made questionnaire including demographic characteristics, clinical and Para clinical symptoms of the patient. It should be noted that patients are asked about the use

Correspondence:
Dr. Mina Jafarabadi
Email: minajaf@yahoo.com
of all therapeutic supplements (multivitamin, vitamin C, vitamin E, folic acid, iron, omega 3 and omega 6) in the last three months. In the case of patients with critical disease conditions; these questions were asked of the patient's first-degree relatives or from their medical records.

Statistical analysis: After collecting the required information, the data were analyzed using SPSS version 21 software. Frequency and frequency percentages were calculated for qualitative variables. Means and standard deviations were determined for Quantitative variables. The significance level was considered as 0.05 to interpret the relationships among the variables. Distribution of variables in this study was not normal, which was assessed by the Mann–Whitney test instead of t independent -test, and then the p-value were extracted. The quantitative variables were compared between the two groups by t-test and Mann–Whitney test. The qualitative variables were compared using Chi-square.

Adjusted Multivariate binary logistic regression was used to examine the variable in relation to odds of COVID-19 in inpatients compared to outpatients groups. Multi nominal Logistic Regression was also used to obtain factors affecting the severity of this disease.

Results

The study was performed on 510 patients with acute respiratory symptoms in the infectious department of the Imam Khomeini hospital. Depending on the severity of the clinical symptoms and lung scan, Patients were divided into two groups: 171 patients who were admitted in hospital (inpatient) and 339 patients were treated on an outpatient basis. The highest number of hospitalizations was reported in people over 60 years and non-hospitalized or outpatient in people less than 35 years of age. The majority of cases in both outpatient and inpatient were men (P=0.010). In the outpatient group, 48% (163 patients) and in the inpatient group, 64.5% (107 patients) had a history of contact with the infected person, which was a significant difference (P=0.001). In other words, in inpatients group, the history of contact with the infected person in the family and workplace has been reported more. The prevalence of hypertension, diabetes, and anemia was higher in hospitalized patients than outpatients (P<0.05) (Table 1).

The clinical symptoms in both outpatients and inpatients included fatigue, myalgia, headache, chest pain and sore throat which were more common in the outpatient group. Lung CT scans showed that pulmonary infiltration and ground glass image was reported in 99% of hospitalized patients (P = 0.001). As well as, in the majority of hospitalized patients (87%), only ground glass pattern was reported (P=0.001).

Also, Hemoglobin levels were lower in hospitalized patients (P = 0.001). This means that 44 patients (26%) of hospitalized patients had anemia compared to 8 patients (2.5%) of the outpatient group.

As we expected the mild clinical and gastrointestinal symptoms were more common in outpatient, however, a high rate of pulmonary infiltration and ground glass in CT scan and images were observed in hospitalized patients. Furthermore, anemia was more common in hospitalized patients.

In the group of hospitalized patients, 80 patients (47%) were in severe condition and 67 (40%) were in critical condition. However, in the group of outpatients, 320 patients (94%) had a normal condition. There was a significant difference between two groups (P=0.001). It means that most hospitalized patients were in critical condition (Table 2).

The supplement consumption pattern in the two groups of outpatient and inpatient show that supplementary consumption patterns (daily, weekly, monthly and irregular) are not statistically significant in the two groups with COVID 19 (P = 0.162).

However, vitamin D3 intake was reported in 30% (103 patients) of outpatients and 16.5% (28 patients) of hospitalized patients, which is statistically significant (P=0.001). It shows that, the frequency of vitamin D3 consumption in the outpatient group was higher than inpatient group. This significant difference has also been shown in zinc consumption, in 29 patients (9%) outpatients versus 4 patients (2%) inpatients were reported (P=0.007) (Table 2).

It should be noted that patients were also asked about taking all of these supplements such as Multivitamins, Vitamin C, Vitamin E, Acid Folic, Iron, Omega-3 and Omega-6, folic acid. The responses indicated that patients in neither of the two outpatient and inpatient groups had used any of these supplements at all.

According to the large number and high diversity of variables, and some Parameters which independently affected hospitalization, we performed a binary regression test to remove the effect of the disruptors and to eliminate their influence on each other. Finally, it can be concluded that the sex of male, Hemoglobin<10 and hypertension are the risk factors for hospitalization.
Table 1: Analysis of Demographic variables in both outpatient and inpatient groups infected with COVID-19

| Variable                  | Outpatient      | Inpatient       | P-value   |
|---------------------------|-----------------|-----------------|-----------|
| Age (mean ± SD)           | 43.74±13.84     | 58.77±17.43     | 0.0001*   |
| Age group (years)         |                 |                 |           |
| < 35                      | 117(8.2%)       | 14(8.2%)        | 0.0001**  |
| 35-60                     | 176(51.9 %)     | 77(45%)         |           |
| > 60                      | 46(13.6%)       | 80(46.8%)       |           |
| Education                 |                 |                 |           |
| Illiterate                | 1(0.3%)         | 24(14%)         | 0.0001**  |
| High school               | 126(63.7%)      | 96(67%)         |           |
| Undergraduate             | 94(28%)         | 23(14%)         |           |
| Postgraduate              | 28(8%)          | 9(5%)           |           |
| Occupation                |                 |                 |           |
| Unemployed                | 20(6%)          | 17(10%)         | 0.0001**  |
| Worker                    | 24(7%)          | 13(8%)          |           |
| Employee                  | 119(35%)        | 30(17.5%)       |           |
| Retired                   | 8(2%)           | 19(11%)         |           |
| House wife                | 89(26%)         | 42(25%)         |           |
| Free lancer               | 76(22%)         | 49(29%)         |           |
| Gender                    |                 |                 |           |
| Yes                       | 195(57.5%)      | 117(69%)        | 0.014**   |
| No                        | 144(42.5)       | 53(31%)         |           |
| History of Exposure       |                 |                 |           |
| Yes                       | 163(48%)        | 107(64.5%)      | 0.001**   |
| No                        | 176(52%)        | 64(35.5%)       |           |
| History of Smoking        |                 |                 |           |
| Yes                       | 79(23%)         | 33(20%)         | 0.384     |
| No                        | 260(77%)        | 133(80%)        |           |
| History of Drugs          |                 |                 |           |
| Yes                       | 13(4%)          | 10(6%)          | 0.265     |
| History of Chronic Disease|                 |                 |           |
| Hypertension              | 55(16%)         | 68(40%)         | 0.0001**  |
| Heart disease             | 30(9%)          | 40(23%)         | 0.0001**  |
| Diabetic                  | 38(11%)         | 51(30%)         | 0.0001**  |
| Hypothyroid               | 28(8%)          | 8(5%)           | 0.140**   |
| Anemia                    | 8(2.5%)         | 44(26%)         | 0.0001**  |
| History of taking supplement in the last three months | 148(44%) | 55(32%) | 0.0001** |
| Number of supplements type (mean ± SD) | 1±1.53 | 0.67±1.28 | 0.012** |
| ***Obesity                | 30(19%)         | 7(14%)          | 0.69**    |

One of the important and obvious differences between the two groups was their general condition (severe and critical condition). Although some factors did not affect hospitalization and outpatient status, they may affect the patient's condition. Multi nominal regression showed that Hypertension with a probability of 4.9 times (OR=4.997; 95% CI2.433-10.25, p value=0. 0001) and anemia with a probability of 22 times (OR=22.905; 95% CI9.355-56.083, p value=0. 0000) are effective in the severity of the disease. In addition, vitamin D3 intake has a supportive effect and reduces the risk of exacerbation and worsening of the disease. (OR = 0.291; 95% CI 0.102-.0834, p value = 0.022) (Table 4).

Discussion
The results of the present study showed that only vitamin D3 and zinc were used more commonly in outpatients infected with COVID-19 and vitamin D3 intake may be has a supportive effect and reduces the risk of exacerbation and worsening of the disease.
Table 2: Analysis of clinical symptoms and intake of supplement pattern in both outpatient and inpatient groups infected with COVID-19

| Variable                              | Outpatient | Inpatient | P-value |
|---------------------------------------|------------|-----------|---------|
| **Clinical symptom**                  |            |           |         |
| Fever & chilly                        | 176(52%)   | 101(59%)  | 0.126   |
| Cough                                 | 248(73%)   | 118(70%)  | 0.326   |
| Sputum                                | 110(32.5%) | 60(35%)   | 0.566   |
| Myalgia                               | 214(63%)   | 89(52%)   | 0.016   |
| Fatigue                               | 215(63%)   | 72(42%)   | 0.001   |
| **Gastrointestinal symptoms**         |            |           |         |
| Diarrhea                              | 94(28%)    | 41(24%)   | 0.365   |
| Nausea                                | 117(34.5%) | 56(33)    | 0.172   |
| Vomiting                              | 60(18%)    | 38(22%)   | 0.221   |
| Headache                              | 167(50%)   | 54(32%)   | 0.0001  |
| Sweating                              | 41(12%)    | 18(10.5%) | 0.747   |
| Anorexia                              | 141(42%)   | 74(43%)   |         |
| Weakness                              | 86(25.5%)  | 48(28%)   | 0.153   |
| Loss of sense of taste                | 18(5.3%)   | 12(7%)    | 0.439   |
| Chest Pain                            | 48(14%)    | 9(5%)     | 0.003   |
| Sore throat                           | 56(16.5%)  | 14(8%)    | 0.010   |
| **Signs in Lung CT scan**             |            |           |         |
| Consolidation                         | 12(5%)     | 8(5%)     | 0.8/95  |
| Bilateral Pulmonary Infiltration       | 51(21%)    | 43(25%)   | 0.310   |
| Ground-glass Opacity                  | 138(57%)   | 147(87%)  | 0.0001  |
| Bilateral Pulmonary Infiltration & Ground-glass Opacity | 2(1.2%) | 14(1.7%) | 0.445 |
| **Hemoglobin level** (mean ± SD)      | 13.84±1.76 | 12.54±2.43 | 0.001 |
| **BG&RH**                             |            |           |         |
| O                                     | 72(36%)    | 13(47%)   | 0.198   |
| A                                     | 57(28.5%)  | 12(39%)   |         |
| B                                     | 42(20.5%)  | 0         |         |
| AB                                    | 31(5%)     | 3(14%)    |         |
| **General Condition**                 |            |           |         |
| General                               | 320(94%)   | 22(13%)   | 0.0001  |
| Severe                                | 19(6%)     | 80(47%)   |         |
| Critical                              | 0          | 67(40%)   |         |
| **Pattern of Supplement usage**       |            |           |         |
| Daily                                 | 50(34%)    | 26(47%)   | 0.162   |
| Weekly                                | 24(16%)    | 9(16%)    |         |
| Monthly                               | 32(22%)    | 9(16%)    |         |
| Irregular                             | 42(28%)    | 11(21%)   |         |
| **Usage of Vitamin D supplement**     | 103(30%)   | 28(16.5%) | 0.001   |
| **Usage of Zinc supplement**          | 29(9%)     | 4(2%)     | 0.007   |
| **Usage of Multi-vitamin**            | 47(14%)    | 18(10.5%) | 0.286   |

* Mann–Whitney Test, Chi-Square Test

In the development of COVID 19 epidemics, the search for possible antiviral strategies for protection and treatment is of particular importance and urgency. Zinc is recognized to control antiviral and antibacterial immunity and regulate the inflammatory response. Despite the lack of clinical data, certain indications suggest that modulation of zinc status may be beneficial in COVID 19 (13).

It is clear that zinc has antiviral properties against a number of viral species. Although there are no exact studies, it seems that zinc appears to inhibit the enzymatic processes of protease and polymerase viruses, as well as processes such as virus attachment, infection, and non-coverage. In addition, in laboratory conditions, zinc has been shown to inhibit the activity of the RdRp coronavirus, and zinc ionophores prevent coronavirus proliferation (14). Unfortunately, these mechanisms have not been well studied in clinical trials, where zinc supplementations may offer prominent antiviral effects as an adjuvant treatment (15).
Despite some controversial results over the years, Vitamin D appears to play an important role in the regulation of innate immunity in the upper respiratory tract (16). There is also evidence revealing of effects of vitamin D supplementation in the prevention of infections (17). Also, cell culture experiments emphasize that vitamin D has direct anti-viral effects particularly against enveloped viruses. Though vitamin D's anti-viral mechanism has not been fully elucidated, it may be related to the ability of vitamin D to regulate the anti-microbial peptides LL-37 and human beta-defensin (18).

Evidence for supporting the role of vitamin D supplementation in reducing the risk of COVID-19 includes flu prevalence in winter when the 25-hydroxy vitamin D (25 (OH) D) concentration is the lowest rate (6, 19). Also serum 25 (OH) D concentrations decrease with age (20), which may increase the risk of mortality in cases of COVID-19 with increasing age (21). The reasons include less sun exposure time and reduced vitamin D production due to lower levels of 7-dehydro cholesterol in the skin (22). Also, using some medications usually increases with age some of which reduce serum 25 (OH) D concentration (23). A recent review found that vitamin D loading doses of 200,000-300,000 IU in form of 50,000 IU capsules were used to reduce the risk and severity of COVID-19 (24).

The hypothesis that "vitamin D supplementation can reduce the risk of influenza and COVID-19 incidence and death" should be investigated in trials to determine the appropriate doses, serum 25 (OH) D concentrations, and the presence of any safety issues" (6). However, Vitamin D supplementation has been described as a treatment for people infected with COVID-19. But so far, there is little scientific evidence that seems to be insufficient in this regard (25, 6). Although there is conflicting data, available evidence suggests that supplementation with micronutrients with protective roles in the immune system may modulate immune function and reduce the risk of infection (26).
It seems the previous consumption of vitamin D and zinc supplements have been accompanied by the mild condition and lower needs of hospitalization. But, the Randomized controlled trials and large population studies should be conducted to explain the efficacy and mechanism of vitamin D, other Vitamins and micronutrients supplementation as an anti-viral agent.

Limitations include that the data were collected from a single-center study in Tehran and the lack of evaluating variables such as the serum 25 (OH) D concentrations, zinc and other micronutrients in this study. It is recommended to perform the randomized control trials and follow-up studies in two groups of inpatients and outpatients infected with COVID-19 to respond to the preference for using any of Vitamins or micronutrient supplementation.

Conclusion
Zinc and vitamin D is recognized to have anti COVID effects indirectly via immunologic intermediation. According to clinical findings of this study it is suggested that modulation of zinc or vitamin D status may be beneficial in COVID 19.

Conflict of Interests
Authors have no conflict of interests.

Acknowledgments
The study was supported by The Tehran University of Medical sciences grant.

The authors would like to thank the patients and the supporting staff in this study.

References
1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddigue R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
2. Li JY, You Zh, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020; 22: 80–5.
3. National Institutes of Health State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference Statement: multivitamin/mineral supplements and chronic disease prevention. Am J Clin Nutr 2007; 85: 257S-64S.
4. Huang HY, Caballero B, Chang S, Alberg A, Semba RD, Schneyer CR, et al. The Efficacy and Safety of Multivitamin and Mineral Supplement Use To Prevent Cancer and Chronic Disease in Adults: A Systematic Review for National Institutes of Health State-of-the-Science Conference. Ann Intern Med 2006; 145: 372-85.
5. Rautiainen S, Manson JE, Lichtenstein AH, Sesso H. Dietary supplements and disease prevention - a global overview. Nat Rev Endocrinology 2016; 12:407-20.
6. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 2020; 12: 988.
7. Lee J, Hecke OV, Roberts N. Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19. CEBM, The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare 2020.
8. Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2013; 8: e65835.
9. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients 2020; 12: 118I.
10. Elmadfa I, Meyer AL. The Role of the Status of Selected Micronutrients in Shaping the Immune Function. Endocr Metab Immune Disord Drug Targets 2019; 19:1100-15.
11. Li XW, Geng M, Peng Y, Meng L, Lu Sh. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10: 102-8.
12. Tu H, Tu Sh, GAO S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19 ; a global perspective from China. J Infect 2020; 81: 1-9.
13. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med 2020; 46: 17-26.
14. Te Velthuis AJW, Van den Worm SHE, Sims AC, Baric RS, Snijder EJ, Van Hemert MJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010; 6: e1001176.
15. Read SA, Obeid S, Ahlenstiel Ch, Ahlenstiel G The Role of Zinc in Antiviral Immunity. Adv Nutr 2019; 10: 696–710.
16. Bartley J. Vitamin D, innate immunity and upper respiratory tract infection. J Laryngol Otol 2010; 124: 465-9.
17. Laakso I. Vitamin D and respiratory infection in adults. Proc Nutr Soc 2012; 71:90-7.
Supplement Usage in COVID-19

18. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol 2011; 50: 194–200.
19. Martineau AR, Jollie DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583.
20. Vasarhelyi B, Satori A, Olajos F, Szabo A, Beko G. Low vitamin D levels among patients at Semmelweis University: Retrospective analysis during a one-year period. Orv Hetil 2011; 152: 1272–7.
21. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 145–51.
22. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76: 1536–8.
23. Grober U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012; 4: 158–66.
24. Wimalawansa SJ. Global epidemic of coronavirus–COVID-19: What we can do to minimize risks. Eur J Biomed Pharm Sci 2020; 7: 432–8.
25. Annweiler C. COVID-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) 2020. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04344041.
26. Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients 2020; 12: 236.

Citation: Bagheri M, Haghollahi F, Shariat M, Jafarabadi M, Aryamloo P, Rezayof E. Supplement Usage Pattern in a Group of COVID-19 Patients in Tehran. J Fam Reprod Health 2020; 14(3): 158-65.